Location
Gustav Mahlerplein 1B
1082 MS Amsterdam
moderated by Hiroshi Sheraton
Andre Hoekema (Galapagos)
Michaël Dillen (Mithra Pharmaceuticals)
Nathalie ter Wengel (Pfizer)
Sijmen de Vries (Pharming)
……………………………………………………………………………………….
moderated by Bart Delbaere
Geraldine O’Keeffe (LSP)
Sachin Soni (Third Eye)
Servaas Michielssens (Candriam)
……………………………………………………………………………………….
Moderated by Berthold Hummel
Cedric Ververken (Confo Therapeutics)
Geert-Jan Mulder (Forbion)
Vincent Brichard (Paracrine Biologicals)
Fiona de Hemptinne (UCB Ventures)
Jan de Kerpel chats with former Ablynx CEO Edwin Moses on the success story of Ablynx under Moses’ reign and the challenges for ambitious biotech companies in today’s healthcare system.
What’s on the horizon in healthcare? Where are we headed? Influence of AI, data, technology and what that means in practice. For patients, providers and payers. What are the opportunities but also the responsibilities?
Moderated by Martine van de Laar
Robert Metzke (Philips)
Lieke van Kerkhoven (FLOOW2Healthcare)
Bart van Straten (Van Straten Medical)
The former Senior Scientific Advisor of the European Medicines Agency (EMA) shares insights on current regulatory challenges.
Moderated by Els Janssens
…………………………………………………………………………………………
Panel discussion on how to deal with new rules and developments in the medtech landscape: e.g., changes in the regulatory framework for IVD and MD, legal aspects of managed services and digital health solutions and legal risk management.
Moderated by Jan Willem Gerritsen
Anne-Sophie Bricca (Terumo BCT Europe N.V.)
Robert Abbott (Stryker)
Oliver Bisazza (MedTech Europe)
Moderated by Wouter Seinen
Mark-Jan Harte (Aidence)
Lucien Engelen (Transform.Health / Center for the Edge Deloitte)
Jacco Keja (IQVIA)
Dr. Jaap Bonjer (Amsterdam University Medical Centre)
Location
Gustav Mahlerplein 1B
1082 MS Amsterdam